Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta v...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattni, Karan, Hungerford, Daniel, Adams, Sarah, Buchan, Iain, Cheyne, Christopher P., García-Fiñana, Marta, Hall, Ian, Hughes, David M., Overton, Christopher E., Zhang, Xingna, Sharkey, Kieran J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934524/
https://www.ncbi.nlm.nih.gov/pubmed/35307024
http://dx.doi.org/10.1186/s12879-022-07239-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934524/
https://www.ncbi.nlm.nih.gov/pubmed/35307024
http://dx.doi.org/10.1186/s12879-022-07239-z

Ejemplares similares